Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10,000
- 试验地点
- 1
- 主要终点
- Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients
研究概览
简要总结
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.
详细描述
This study combines retrospective and prospective designs.
Retrospective:
We use past electronic medical records to identify participants and collect baseline information from their initial visit (using their code or health card number).
Prospective:
From that starting point, we follow the same participants forward in time, updating data every two years and recording new outcomes (mortality, cardiovascular events, rehospitalizations, treatment-related outcomes) at planned checkpoints (approximately 6 months, 1 year, and 2 years).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Qatari and Arab participants
- •Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)
- •Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%
排除标准
- •Non-Qatari or non-Arab participants
- •Non-diabetic: HbA1C < 5.7%
- •This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.
结局指标
主要结局
Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients
时间窗: 5 years
Composite endpoint defined as the occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Events will be identified using electronic medical records, hospital admission data, and follow-up assessments during the study period. These outcomes will serve as endpoints for the development and validation of predictive machine learning models.
Incidences of 2-point Major Adverse Cardiovascular Events (MACE) in Heart Failure Patients
时间窗: 5 years
Composite endpoint defined as cardiovascular death or hospitalization for heart failure. Events will be ascertained through hospital records, clinical documentation, and follow-up data collection. These outcomes will be used as endpoints for predictive model development and validation.
次要结局
- Arrhythmic events(5 years)
- Coronary revascularization(5 years)
- Post-Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) complications (stent/graft thrombosis or repeat revascularization)(5 years)
- Development or progression of valvular heart disease (aortic or mitral stenosis/regurgitation)(5 years)
- New-onset diabetes mellitus(5 years)
- Change in glycated Hemoglobin A1c (HbA1c)(5 years)
- Newly diagnosed medical or surgical conditions not present at baseline(5 years)
- Major Adverse Cardiovascular Events(5 years)
- Unstable angina requiring hospitalization(5 years)